A research collective from across the USA including from Emory University (Atlanta, GA, USA) and Stanford University (CA, USA), among others, have developed a new vaccine for HIV, which is better at preventing infection as well as lasting for a year after inoculation. The new vaccine marked improvement is down to exploiting alliance between neutralizing antibodies and cellular immunity. “Most efforts to develop an HIV vaccine focus on activating the immune system to make antibodies that can inactivate the virus, so called neutralizing antibodies,” explained Eric Hunter, Professor at Emory, and a researcher at the Emory Vaccine Center (EVC; GA,...
To view this content, please register now for access
Join our member community for FREE to access a collection of journal and online-only features, including:
- Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
- The latest news and journal updates delivered straight to your inbox when you want it
- Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
- Priority registration to webinars, panel discussions and events
- Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!